6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes
Key Takeaways
Hormone receptor testing via immunohistochemistry (IHC) classifies breast carcinomas as ER/PR positive (1% or greater immunoreactive cells), ER-low positive (1% to 10%), or negative (less than 1%), predicting responsiveness to endocrine therapies.
HER2 testing follows ASCO/CAP guidelines: IHC 0 and 1+ are negative, IHC 2+ is equivocal requiring reflex dual-probe FISH testing, and IHC 3+ is positive.
The HER2-low category (IHC 1+ or IHC 2+ with non-amplified FISH) identifies patients eligible for targeted antibody-drug conjugates such as trastuzumab deruxtecan rather than traditional HER2 receptor blockade.
The Ki-67 proliferation index reflects cellular growth fraction, with thresholds differentiating indolent Luminal A tumors (typically less than 14% to 20%) from proliferative Luminal B tumors.
Intrinsic molecular classification categorizes breast carcinomas into Luminal A, Luminal B, HER2-enriched, and Triple-Negative/Basal-like subtypes, governing biologic aggressiveness, recurrence timing, and systemic therapy selection.
Biomarker assessment is the foundation of modern personalized breast oncology. Pathologic evaluation of invasive breast carcinoma goes beyond anatomic tumor dimensions to characterize specific molecular receptors that dictate biologic aggressiveness, risk of recurrence, and sensitivity to targeted systemic therapies. Breast care nurses must understand the clinical distinction between prognostic biomarkers, which provide information about overall patient outcome independent of treatment, and predictive biomarkers, which forecast the likelihood of therapeutic response to a specific pharmacological agent.
Hormone Receptor Testing: ER and PR
Estrogen receptor (ER) and progesterone receptor (PR) expression is evaluated on all newly diagnosed invasive breast carcinomas and recurrences. Testing is routinely performed via immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) tissue sections.
ASCO/CAP Interpretation Guidelines
The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) establish strict criteria for interpreting hormone receptor status based on the percentage of invasive tumor cell nuclei demonstrating immunoreactivity:
- ER/PR Positive: Staining present in 1% or greater of invasive tumor cell nuclei. Patients with tumors demonstrating 1% or greater expression are candidates for adjuvant endocrine therapy.
- ER-Low Positive: Staining present in 1% to 10% of invasive tumor cell nuclei. The ASCO/CAP guidelines recommend reporting this distinct subgroup because clinical trial data show that tumors with 1% to 10% ER expression exhibit heterogeneous biology, frequently behave similarly to ER-negative or basal-like carcinomas, and derive limited or uncertain benefit from endocrine therapy.
- ER/PR Negative: Staining present in less than 1% or 0% of invasive tumor cell nuclei. Endocrine therapy is not indicated for ER-negative tumors.
Pre-Analytical Quality Requirements
Hormone receptor proteins are labile and prone to enzymatic degradation following tissue devascularization. ASCO/CAP guidelines mandate rigorous pre-analytical controls:
- Cold Ischemia Time: The interval from surgical tissue removal (or core biopsy devascularization) to immersion in chemical fixative must be recorded and kept under 1 hour (optimally 30 minutes or less).
- Fixation Duration: Specimens must be immersed in 10% neutral buffered formalin for a minimum of 6 hours up to a maximum of 72 hours. Under-fixation (less than 6 hours) or over-fixation (exceeding 72 hours) causes false-negative or variable staining results.
Clinical and Predictive Significance
ER and PR serve both prognostic and predictive roles. Prognostically, hormone receptor-positive tumors generally follow a more indolent early natural history than receptor-negative tumors, though late recurrences beyond 5 to 10 years remain a persistent risk. Predictively, ER positivity is the strongest predictor of clinical benefit from endocrine modalities, including selective estrogen receptor modulators (e.g., tamoxifen), aromatase inhibitors (e.g., anastrozole, letrozole, exemestane), and selective estrogen receptor downregulators (e.g., fulvestrant). Robust PR expression (20% or greater) reflects an intact, estrogen-regulated transcriptional pathway; tumors that are ER-positive but PR-negative often demonstrate higher genomic instability, increased growth factor signaling, and reduced endocrine sensitivity.
Human Epidermal Growth Factor Receptor 2 (HER2) Testing
HER2 (encoded by the ERBB2 gene on chromosome 17q12) is a transmembrane receptor tyrosine kinase belonging to the epidermal growth factor receptor family. Approximately 15% to 20% of invasive breast cancers exhibit HER2 gene amplification and protein overexpression, which historically drove aggressive tumor proliferation, early visceral dissemination, and poor clinical outcomes.
ASCO/CAP HER2 Testing Algorithm
ASCO/CAP guidelines mandate initial testing of all primary invasive breast cancers using IHC, with reflex in situ hybridization (ISH) for indeterminate cases:
- IHC 0 (Negative): No staining observed, or membrane staining that is incomplete and faint or barely perceptible within 10% or less of invasive tumor cells.
- IHC 1+ (Negative): Incomplete membrane staining that is faint or barely perceptible within greater than 10% of invasive tumor cells.
- IHC 2+ (Equivocal): Weak to moderate complete membrane staining observed in greater than 10% of invasive tumor cells. An IHC 2+ result cannot be used to guide therapy and mandates reflex testing with dual-probe fluorescence in situ hybridization (FISH) on the same specimen or an alternate block.
- IHC 3+ (Positive): Circumferential membrane staining that is complete and intense within greater than 10% of invasive tumor cells. Patients are eligible for HER2-targeted therapies.
Dual-Probe In Situ Hybridization (FISH) Criteria
Dual-probe FISH quantifies both HER2 gene copies and chromosome 17 centromere (CEP17) signals within invasive tumor nuclei, reporting the HER2/CEP17 ratio and the average HER2 copy number per cell:
- Group 1 (Positive): HER2/CEP17 ratio of 2.0 or greater and average HER2 copy number of 4.0 or greater signals per cell.
- Group 2: HER2/CEP17 ratio of 2.0 or greater but average HER2 copy number below 4.0 per cell. Final status depends on concurrent IHC: negative if IHC is 0 or 1+; if IHC is 2+, a second reader recounts and the tumor is called negative (with a comment) unless the recount changes the group; positive if IHC is 3+.
- Group 3: HER2/CEP17 ratio below 2.0 with average copy number of 6.0 or more. Positive if IHC is 3+, or if IHC is 2+ and the recount confirms Group 3; negative if IHC is 0 or 1+.
- Group 4: HER2/CEP17 ratio below 2.0 with average copy number of 4.0 to 5.9. Since the 2018 ASCO/CAP update this is reported as HER2-negative (with a comment) unless concurrent IHC is 3+.
- Group 5 (Negative): HER2/CEP17 ratio of less than 2.0 and average HER2 copy number of less than 4.0 signals per cell.
The HER2-Low Paradigm
Historically, breast cancer was classified dichotomously as HER2-positive or HER2-negative. However, clinical advances have defined a clinically actionable intermediate group designated HER2-low, defined as:
- Tumors with an IHC score of 1+, or
- Tumors with an IHC score of 2+ and negative (non-amplified) FISH.
HER2-low tumors constitute approximately 50% to 60% of all breast cancers, with the majority being ER-positive. Landmark clinical trials (such as DESTINY-Breast04) demonstrated that patients with HER2-low metastatic breast cancer achieve substantial progression-free and overall survival benefits from the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd). Traditional HER2-targeted agents (such as trastuzumab and pertuzumab) require marked HER2 overexpression (IHC 3+) to interrupt oncogenic driver signaling. In contrast, T-DXd uses the HER2 receptor merely as a target for cellular internalization; once internalized, the topoisomerase I inhibitor payload is cleaved and diffuses across cell membranes to eradicate neighboring tumor cells (the bystander killing effect), regardless of individual target expression.
In January 2025 the FDA extended T-DXd to HER2-ultralow metastatic disease (IHC 0 with faint, incomplete membrane staining in 10% or fewer of tumor cells) after at least one endocrine therapy, based on DESTINY-Breast06. Pathologists are therefore asked to separate IHC 0 with no staining ("HER2-null") from ultralow staining.
Ki-67 Proliferation Index
Ki-67 is a nuclear non-histone protein expressed during all active phases of the cell cycle (G1, S, G2, and mitosis) but strictly absent in quiescent (G0) cells. Measured by IHC, the Ki-67 labeling index represents the percentage of malignant cells undergoing active proliferation:
- Low Proliferation: Ki-67 index less than 14% to 20%.
- High Proliferation: Ki-67 index greater than 20%.
While inter-laboratory analytical variability exists, Ki-67 provides valuable prognostic information and aids in distinguishing indolent Luminal A carcinomas from more aggressive Luminal B carcinomas. It also assists in identifying hormone receptor-positive patients who may harbor elevated recurrence risk warranting adjuvant CDK4/6 inhibitor therapy (monarchE enrolled a Ki-67 ≥20% cohort, but since March 2023 the FDA label for adjuvant abemaciclib no longer requires a Ki-67 result).
Intrinsic Molecular Subtypes
Gene expression profiling (the Perou and Sørlie classification) identifies four principal intrinsic molecular subtypes of breast cancer, which are approximated in routine clinical practice using surrogate IHC and FISH biomarkers.
| Molecular Subtype | Surrogate Biomarker Profile | Histologic Grade | Clinical Behavior & Metastatic Patterns | Standard Systemic Therapy Strategies |
|---|---|---|---|---|
| Luminal A | ER positive, PR high (20% or greater), HER2 negative, Ki-67 low (less than 14% to 20%) | Grade 1 or 2 | Indolent course; low early recurrence; late recurrences may occur beyond 5 years; predilection for bone metastases | Endocrine therapy alone (tamoxifen or aromatase inhibitor); cytotoxic chemotherapy rarely beneficial |
| Luminal B (HER2-negative) | ER positive, PR low (less than 20%) or negative, HER2 negative, Ki-67 high (20% or greater) | Grade 2 or 3 | Moderately aggressive; higher early recurrence risk than Luminal A; bone and soft tissue metastases common | Endocrine therapy plus adjuvant chemotherapy; consider CDK4/6 inhibitor for high clinical/genomic risk |
| Luminal B (HER2-positive) | ER positive, any PR status, HER2 positive (IHC 3+ or FISH amplified), any Ki-67 | Grade 2 or 3 | Aggressive growth driven by dual hormone and HER2 signaling; bone, visceral, and CNS recurrence risk | Chemotherapy combined with dual HER2-targeted blockade (trastuzumab and pertuzumab), followed by endocrine therapy |
| HER2-Enriched | ER negative, PR negative, HER2 positive (IHC 3+ or FISH amplified), high Ki-67 | Grade 3 | Highly proliferative; high risk of early recurrence within 3 to 5 years; predilection for visceral (liver, lung) and brain metastases | Neoadjuvant/adjuvant chemotherapy plus dual HER2-targeted blockade; antibody-drug conjugates (T-DM1, T-DXd) for residual/metastatic disease |
| Triple-Negative / Basal-Like | ER negative (less than 1%), PR negative (less than 1%), HER2 negative (IHC 0, 1+, or 2+/FISH-), high Ki-67 | Grade 3 | Highly aggressive; early peak of recurrence at 2 to 3 years; frequent visceral, pleural, and CNS metastases; strong association with germline BRCA1 mutations | Cytotoxic chemotherapy (taxanes, anthracyclines, platinum agents); immune checkpoint inhibitors (pembrolizumab); PARP inhibitors for germline BRCA carriers |
Nursing Considerations in Biomarker Evaluation
Breast care nurses serve as vital navigators when diagnostic biomarker results are reported:
- Specimen Stewardship: Coordinate clinical workflows to verify that cold ischemia time is documented and kept under 1 hour, and that tissue specimens are transferred promptly to pathology for formalin fixation.
- Patient Education: Demystify complex pathology terminology. Clarify that "positive" hormone receptor status is a favorable prognostic attribute indicating therapeutic vulnerability, whereas "negative" status indicates an absence of that specific hormonal target.
- Clarifying the HER2-Low Status: Explain to patients that being classified as "HER2-low" does not mean they have HER2-positive disease or qualify for standard trastuzumab; rather, it identifies a target for specialized antibody-drug conjugates should advanced disease develop.
- Multidisciplinary Alignment: Facilitate referral to genetic counseling for every patient diagnosed with triple-negative breast cancer (an NCCN testing criterion at any age), given the high prevalence of germline BRCA1 and PALB2 variants.
A pathology report for an invasive ductal carcinoma demonstrates 8% nuclear immunoreactivity for estrogen receptors (ER), 0% for progesterone receptors (PR), and an IHC score of 1+ for HER2. According to ASCO/CAP guidelines, how is the estrogen receptor status correctly categorized, and what is its clinical significance?
ER-low positive (1% to 10%); the tumor may derive limited benefit from endocrine therapy and exhibits biologic features often resembling ER-negative disease.
ER-negative (less than 10%); the tumor must be managed exclusively as triple-negative breast cancer without any endocrine therapy.
ER-positive (1% or greater); the tumor possesses standard high hormonal sensitivity identical to carcinomas with 80% to 100% nuclear staining.
Equivocal; the specimen mandates reflexive gene amplification testing via in situ hybridization to confirm receptor expression.
A 56-year-old patient with newly diagnosed invasive mammary carcinoma receives an immunohistochemistry (IHC) score of 2+ for HER2. What is the mandatory next step to determine definitive HER2 gene status according to ASCO/CAP guidelines?
Initiate adjuvant trastuzumab immediately based on the presence of weak-to-moderate complete membrane staining.
Perform reflexive dual-probe in situ hybridization (FISH) to assess HER2 gene amplification.
Repeat the core needle biopsy to obtain additional tissue for repeat immunohistochemistry testing.
Classify the tumor as HER2-low and initiate single-agent aromatase inhibitor monotherapy.
Which intrinsic molecular subtype of breast cancer is characterized by estrogen receptor positivity, high progesterone receptor expression (20% or greater), HER2 negativity, a low Ki-67 proliferation index (less than 14%), and the most favorable long-term prognosis with endocrine therapy alone?
Luminal B (HER2-negative)
HER2-enriched
Luminal A
Basal-like / Triple-negative
Sections you finish are checked off in the contents.